Periodate and recombinant interleukin-2-activated autologous leukocytes can induce regression of metastases of renal cancer.

A. J. Walle, J. Wang, A. Novogrodsky, Manikkam Suthanthiran, B. Gordon, A. L. Rubin, K. H. Stenzel

Research output: Contribution to journalArticle

Abstract

We present the results of a pilot study that determined the effects of both intermittent injections of periodate and recombinant interleukin-2 (rIL-2)-activated leukocytes and continuous infusions of low doses of rIL-2 on metastases of nine patients with stage IV renal cancer. Four patients experienced regressions, two patients stabilized, and only three patients did not respond. The responses of individual lesions in six patients were heterogeneous with regard to both the degree (ranging from cessation of growth to regression to undetectability) and the duration (ranging from less than 3 to up to 8 months). Survival times from the time of diagnosis and from the time of start of the protocol treatment ranged from 12 to 20 months and 6 to 12 months, respectively, for three patients who expired and from 10+ to 28+ months and 6+ to 12+ months, respectively, for six patients who are alive. Only one patient experienced a grade 4 toxicity (transient renal failure requiring hemodialysis). All other toxicities (grades 1-3) were easily controlled and resolved completely after 7 days. This pilot study deserves clinical testing on a larger scale, since it combines regression inductions in a hitherto treatment-resistant cancer with little complicating toxicity.

Original languageEnglish
Pages (from-to)395-411
Number of pages17
JournalCancer Detection and Prevention
Volume12
Issue number1-6
Publication statusPublished - 1 Jan 1988
Externally publishedYes

Fingerprint

Kidney Neoplasms
Interleukin-2
Leukocytes
Neoplasm Metastasis
metaperiodate
Clinical Protocols
Renal Insufficiency
Renal Dialysis
Injections
Survival
Growth

ASJC Scopus subject areas

  • Oncology

Cite this

Periodate and recombinant interleukin-2-activated autologous leukocytes can induce regression of metastases of renal cancer. / Walle, A. J.; Wang, J.; Novogrodsky, A.; Suthanthiran, Manikkam; Gordon, B.; Rubin, A. L.; Stenzel, K. H.

In: Cancer Detection and Prevention, Vol. 12, No. 1-6, 01.01.1988, p. 395-411.

Research output: Contribution to journalArticle

Walle, A. J. ; Wang, J. ; Novogrodsky, A. ; Suthanthiran, Manikkam ; Gordon, B. ; Rubin, A. L. ; Stenzel, K. H. / Periodate and recombinant interleukin-2-activated autologous leukocytes can induce regression of metastases of renal cancer. In: Cancer Detection and Prevention. 1988 ; Vol. 12, No. 1-6. pp. 395-411.
@article{e2af16396d1d48f999d77da79ae4670b,
title = "Periodate and recombinant interleukin-2-activated autologous leukocytes can induce regression of metastases of renal cancer.",
abstract = "We present the results of a pilot study that determined the effects of both intermittent injections of periodate and recombinant interleukin-2 (rIL-2)-activated leukocytes and continuous infusions of low doses of rIL-2 on metastases of nine patients with stage IV renal cancer. Four patients experienced regressions, two patients stabilized, and only three patients did not respond. The responses of individual lesions in six patients were heterogeneous with regard to both the degree (ranging from cessation of growth to regression to undetectability) and the duration (ranging from less than 3 to up to 8 months). Survival times from the time of diagnosis and from the time of start of the protocol treatment ranged from 12 to 20 months and 6 to 12 months, respectively, for three patients who expired and from 10+ to 28+ months and 6+ to 12+ months, respectively, for six patients who are alive. Only one patient experienced a grade 4 toxicity (transient renal failure requiring hemodialysis). All other toxicities (grades 1-3) were easily controlled and resolved completely after 7 days. This pilot study deserves clinical testing on a larger scale, since it combines regression inductions in a hitherto treatment-resistant cancer with little complicating toxicity.",
author = "Walle, {A. J.} and J. Wang and A. Novogrodsky and Manikkam Suthanthiran and B. Gordon and Rubin, {A. L.} and Stenzel, {K. H.}",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "12",
pages = "395--411",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier BV",
number = "1-6",

}

TY - JOUR

T1 - Periodate and recombinant interleukin-2-activated autologous leukocytes can induce regression of metastases of renal cancer.

AU - Walle, A. J.

AU - Wang, J.

AU - Novogrodsky, A.

AU - Suthanthiran, Manikkam

AU - Gordon, B.

AU - Rubin, A. L.

AU - Stenzel, K. H.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - We present the results of a pilot study that determined the effects of both intermittent injections of periodate and recombinant interleukin-2 (rIL-2)-activated leukocytes and continuous infusions of low doses of rIL-2 on metastases of nine patients with stage IV renal cancer. Four patients experienced regressions, two patients stabilized, and only three patients did not respond. The responses of individual lesions in six patients were heterogeneous with regard to both the degree (ranging from cessation of growth to regression to undetectability) and the duration (ranging from less than 3 to up to 8 months). Survival times from the time of diagnosis and from the time of start of the protocol treatment ranged from 12 to 20 months and 6 to 12 months, respectively, for three patients who expired and from 10+ to 28+ months and 6+ to 12+ months, respectively, for six patients who are alive. Only one patient experienced a grade 4 toxicity (transient renal failure requiring hemodialysis). All other toxicities (grades 1-3) were easily controlled and resolved completely after 7 days. This pilot study deserves clinical testing on a larger scale, since it combines regression inductions in a hitherto treatment-resistant cancer with little complicating toxicity.

AB - We present the results of a pilot study that determined the effects of both intermittent injections of periodate and recombinant interleukin-2 (rIL-2)-activated leukocytes and continuous infusions of low doses of rIL-2 on metastases of nine patients with stage IV renal cancer. Four patients experienced regressions, two patients stabilized, and only three patients did not respond. The responses of individual lesions in six patients were heterogeneous with regard to both the degree (ranging from cessation of growth to regression to undetectability) and the duration (ranging from less than 3 to up to 8 months). Survival times from the time of diagnosis and from the time of start of the protocol treatment ranged from 12 to 20 months and 6 to 12 months, respectively, for three patients who expired and from 10+ to 28+ months and 6+ to 12+ months, respectively, for six patients who are alive. Only one patient experienced a grade 4 toxicity (transient renal failure requiring hemodialysis). All other toxicities (grades 1-3) were easily controlled and resolved completely after 7 days. This pilot study deserves clinical testing on a larger scale, since it combines regression inductions in a hitherto treatment-resistant cancer with little complicating toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0023725968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023725968&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 395

EP - 411

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

IS - 1-6

ER -